文献速递糖尿病

DURATION-8研究:艾塞那肽联合达格列净治疗2年的疗效与安全性——多中心、双盲、3期随机对照试验

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
PubMed 文献 · Diabetes Care · 2020-08-18

DURATION-8为104周多中心双盲3期随机对照试验,695例二甲双胍控制不佳的2型糖尿病患者按1:1:1接受艾塞那肽每周一次联合达格列净、艾塞那肽联合安慰剂或达格列净联合安慰剂治疗。第104周时,联合组HbA1c降幅大于两个单药组,未发现意外安全性问题,无严重低血糖发作;所有104周评估均为探索性分析。

要点

  • 第104周时,艾塞那肽联合达格列净组HbA1c降幅大于艾塞那肽联合安慰剂组和达格列净联合安慰剂组。
  • 联合组在空腹血糖、餐后2小时血糖、体重和收缩压方面也观察到临床相关变化。
  • 联合治疗耐受性良好,无严重低血糖发作,未发现意外安全性问题。

核心结论

  • 在完成试验且未使用补救治疗的患者中,艾塞那肽每周一次联合达格列净治疗2年具有临床相关疗效,未发现意外安全性问题;该分析为探索性分析。

研究设计与样本

  • DURATION-8为104周、多中心、双盲、随机、阳性对照、3期试验。
  • 共695例年龄≥18岁、二甲双胍单药治疗(≥1,500 mg/天)稳定但血糖控制不佳(HbA1c 8.0-12.0% [64-108 mmol/mol])的2型糖尿病成人患者,按1:1:1随机分配至艾塞那肽2 mg每周一次联合达格列净10 mg每日一次、艾塞那肽每周一次联合安慰剂、或达格列净联合安慰剂。
  • 所有104周评估均为探索性分析。

主要发现

  • 第104周时,431例(62.0%)患者完成治疗。
  • 第104周HbA1c自基线的校正最小二乘均值变化(SE):艾塞那肽联合达格列净组为-1.70%(0.11),大于艾塞那肽联合安慰剂组的-1.29%(0.12)(P=0.007)和达格列净联合安慰剂组的-1.06%(0.12)(P<0.001)。
  • 艾塞那肽联合达格列净组在空腹血糖、餐后2小时血糖、体重和收缩压方面也观察到临床相关变化。
  • 未发现意外安全性问题,艾塞那肽联合达格列净耐受性良好,无严重低血糖发作。

临床怎么用

  • 原文未据此给出推荐;作者在结论中指出,在完成试验且未使用补救治疗的患者中,艾塞那肽每周一次联合达格列净治疗2年具有临床相关疗效,未发现意外安全性问题。

局限性

  • 所有104周评估均为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS: DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged ≥18 years) with type 2 diabetes and inadequate glycemic control (HbA1c 8.0-12.0% [64-108 mmol/mol]) despite stable metformin monotherapy (≥1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS: At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA1c was greater with exenatide QW plus dapagliflozin (-1.70% [0.11]) versus exenatide QW plus placebo (-1.29% [0.12]; P = 0.007) and dapagliflozin plus placebo (-1.06% [0.12]; P < 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS: In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Jabbour SA, Frías JP, Ahmed A, et al. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care. 2020. PMID: 32816874. doi:10.2337/dc19-1350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。